New Study in JAMA Network Open Shows Current Approaches to Assessing Preeclampsia Risk Are Failing the Majority of Pregnant Moms
A new study sponsored by Mirvie, which is the first to evaluate U.S. Preventive Services Task Force (USPSTF) guidelines for preeclampsia risk and aspirin prescription in a single, nationally representative, prospective population, found while high-risk factors had sufficient value in estimating risk, there’s limited value for the moderate risk category - leading to nonspecific recommendations for aspirin use, a recognized prevention tool.
Introducing Encompass™: A Breakthrough Solution from Mirvie to Advance Care for Pregnancy Complications
Mirvie, a leader in uncovering the biology and utilizing data-driven approaches to improve the care of women’s health conditions, today announced the launch of its first breakthrough product for preeclampsia, one of the most common and serious pregnancy complications. Encompass™ combines a novel blood test to predict personalized preeclampsia risk with a preventive action plan and a responsive virtual assistant to offer pregnant women individualized support and help them work with their care team towards the healthiest pregnancy possible.
Mirvie Announces Results from Largest Molecular Study in Pregnancy and Clinical Validation of Simple Blood Test to Predict Risk for Preeclampsia Months Before Symptoms
Today, Mirvie announced results of a breakthrough study published in Nature Communications, revealing new advances in the biological understanding of hypertensive disorders of pregnancy (HDP), including preeclampsia - a leading cause of maternal morbidity and mortality as well as preterm birth. Researchers used data from more than 9,000 pregnancies within the multi-center Mirvie-sponsored Miracle of Life prospective study to discover and validate RNA signatures capable of distinguishing between severe and mild hypertensive disorders of pregnancy, including preeclampsia, months before symptoms occur. The paper also validates the predictive performance of Mirvie’s simple blood test to predict preeclampsia early, at 17.5 to 22 weeks gestational age, in pregnancies without any pre-existing high-risk conditions.
Mirvie RNA Platform First to Uncover Unique Molecular Signal for Babies at Risk of Severe Fetal Growth Restriction
Mirvie, a pioneer in bringing a personalized, predictive, and preventive approach to serious pregnancy complications, today announced at the Society for Maternal-Fetal Medicine annual meeting that the Mirvie RNA platform has uncovered a unique molecular signature predictive for babies born with severe growth restriction. Unrecognized fetal growth restriction is the single largest risk factor for stillbirth.
Research Using Mirvie RNA Platform Selected for Plenary Session Presentation at the Society for Maternal and Fetal Medicine Annual Meeting
Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced the company was selected to present new research demonstrating the ability of the Mirvie RNA platform to predict the risk of severe fetal growth restriction in pregnancy.
New Campaign Brings to Forefront How Preeclampsia Prevention is Possible for Pregnant Women
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, “Preeclampsia Prevention is Possible.” The campaign elevates awareness of a major paradigm shift underway focused on the prevention of the disease, encouraging the use of evidence-based strategies so pregnant patients and providers can actively work together to create the healthiest pregnancy possible.
Mirvie Announces Completion of Enrollment of 10,000 Person Landmark Research Study for Pregnancy Health
Mirvie, a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.
Mirvie Becomes First RNA-Based Pregnancy Health-Focused Company to Receive Clinical Laboratory Improvement Amendments (CLIA) Certification
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced its South San Francisco-based laboratory has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.
Mirvie Receives $4.6 Million Grant to Study Objective Prediction of Preeclampsia in Sub-Saharan Africa
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced a $4.6 million grant from the Bill & Melinda Gates Foundation to support the company’s efforts to predict unexpected pregnancy complications before they happen by revealing the underlying biology of each pregnancy for women on a global scale. Specifically, the funding will help launch study sites in Cameroon, Ghana, and Zambia to understand preeclampsia among pregnant women in low- and middle-income countries (LMIC) using the Mirvie RNA platform via a simple blood test from the mom.
First Comprehensive Care Plan to Prevent Preeclampsia Published in the American Journal of Obstetrics and Gynecology
A new special report published in the American Journal of Obstetrics and Gynecology (AJOG) provides a groundbreaking approach to preeclampsia, one of the most pressing issues in maternal health today and will translate the prediction of risk into prevention of disease.
First Ever “Future of Pregnancy Health” Report Reveals 9 out of 10 New or Expecting Moms Want More Information About Their Individual Risk of Pregnancy Complications to Optimize Prevention
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the findings of the first ever “Future of Pregnancy Health” Report. The report’s actionable insights to improve pregnancy health in the United States are urgently needed. Maternal mortality is on the rise and hypertensive disorders of pregnancy, including preeclampsia, are leading causes of death and have doubled between 2007 and 2019.1
Mirvie Expands Leadership Team with Appointment of Alison Cowan, M.D. as Head of Medical Affairs
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the appointment of Alison Cowan, M.D., M.S.C.R. as Head of Medical Affairs. Dr. Cowan will guide Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.[1],[2]
Mirvie Raises $60 Million Funding Round to Shape the Future of Pregnancy Health
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced it has raised a total of $90 million to date following the close of its Series B funding. The financing was led by Decheng Capital with additional funding from funds and accounts managed by BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield as well as a debt facility with Comerica Bank. The funding will support Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is the first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.[1],[2]
Mirvie Receives FDA Breakthrough Device Designation for First Test Designed to Indicate Risk of Preeclampsia Months Before Symptoms Occur
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the company received U.S. Food and Drug Administration (FDA) Breakthrough Device designation for its test to indicate a woman’s individualized risk of developing preeclampsia before symptoms occur. The test is powered by the proprietary Mirvie RNA platform, which is designed to predict the risk of unexpected complications by revealing the underlying biology of each pregnancy.[1], [2]
Study Published in The American Journal of Obstetrics and Gynecology Shows The Mirvie RNA Platform is First to Predict Preterm Birth by Revealing the Underlying Biology of Each Pregnancy
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the publication of a study in the American Journal of Obstetrics and Gynecology, a leading obstetrics and gynecology medical journal. The results demonstrate the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy. The breakthrough research shows the platform can predict the condition months before symptoms occur and identify distinct biological pathways driving its development.
Late-breaking Data Presented at SMFM 2022 Annual Meeting Shows The Mirvie RNA Platform is First to Reveal The Underlying Biology of Preterm Birth
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced data presented at the Society for Maternal-Fetal Medicine 42nd Annual Pregnancy Meeting (SMFM 2022) demonstrates the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy. The breakthrough research shows the platform can predict the condition months before symptoms occur and identify distinct biological pathways driving its development.
Study Published in Nature Shows Mirvie Can Predict Pregnancy Complications Months Before They Happen Using New, Proprietary RNA Platform
Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the publication of a study in Nature proving the proprietary Mirvie RNA platform is first to predict unexpected complications by revealing the underlying biology of each pregnancy. The research analyzed the largest and most diverse dataset of maternal transcriptomes to date. The platform opens a new window into pregnancy health for women to act and their doctors to intervene before unexpected complications become a crisis.
